Autologous hematopoietic stem cell (HSC) transplant is an effective treatment for patients with hematological malignancies. Unfortunately, 15-30% of patients fail to mobilize a sufficient number of HSCs for the transplant. Plerixafor is now used as a salvage mobilization regimen, with good success. We describe here a risk-based approach for the use of plerixafor, based on the circulating CD34 + cell count and the CD34 + cell dose collected after 4 days of G-CSF, that identifies potential poor HSC mobilizers upfront. A total of 159 patients underwent HSC collections using this approach. Of these, 55 (35%) were identified as high risk owing to low CD34 + cell number or low yield on day 1 of collection, and received plerixafor on the subsequent days of collection. Of the 159 patients, 151 (95%) were able to provide adequate collections with the first mobilization attempt in a median of 1.7 days using this approach. Of the eight who failed initial mobilization, 5 successfully underwent re-mobilization with plerixafor and G-CSF and 3 (1.9%) were mobilization failures. This approach helped to control the overall cost of HSC collections for our BMT program by decreasing the need for remobilization, reducing the number of collection days and avoiding the use of plerixafor in all patients.
Autologous hematopoietic stem cell (HSC) transplant is an effective treatment for patients with hematological malignancies. Unfortunately, 15-30% of patients fail to mobilize a sufficient number of HSCs for the transplant. Plerixafor is now used as a salvage mobilization regimen, with good success. We describe here a risk-based approach for the use of plerixafor, based on the circulating CD34 + cell count and the CD34 + cell dose collected after 4 days of G-CSF, that identifies potential poor HSC mobilizers upfront. A total of 159 patients underwent HSC collections using this approach. Of these, 55 (35%) were identified as high risk owing to low CD34 + cell number or low yield on day 1 of collection, and received plerixafor on the subsequent days of collection. Of the 159 patients, 151 (95%) were able to provide adequate collections with the first mobilization attempt in a median of 1.7 days using this approach. Of the eight who failed initial mobilization, 5 successfully underwent re-mobilization with plerixafor and G-CSF and 3 (1.9%) were mobilization failures. This approach helped to control the overall cost of HSC collections for our BMT program by decreasing the need for remobilization, reducing theIntroduction High-dose chemotherapy and autologous transplantation utilizing hematopoietic stem cells (HSC) has become an essential procedure in the management of non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, germ cell tumors and some non-malignant diseases.
1,2 Adequate HSC mobilization is required for patients to undergo auto-SCT successfully. HSC mobilization is generally performed using G-CSF, alone or in combination with chemotherapy. 3 With this strategy the majority of patients will have an adequate stem cell collection; however, about 15-30% of patients will fail to yield an optimal HSC dose. [4] [5] [6] Patients who fail to mobilize adequate stem cells will then have difficulty proceeding to an autologous transplant in a timely manner, or may be unable to undergo the potentially life-saving transplant procedure.
Plerixafor, a macrocyclic compound, is a partial antagonist of the a-chemokine receptor CXCR4 and an allosteric antagonist of CXCR7. It reversibly inhibits stromal derived factor-1 binding to CXCR4. 7 It has been shown that an interaction between stromal derived factor-1 ligand and chemokine receptor CXCR4 is important for stem cell mobilization. 8 If this interaction can be interrupted, there is a rapid egress of hematopoietic stem cells and progenitor cells from the BM. Initial studies with plerixafor showed a dose-dependent increase in hematopoietic stem cells and progenitor cells in peripheral blood after administration. 9 More recent studies have shown that plerixafor, in conjunction with G-CSF, was successful in adequate HSC mobilization in patients who failed mobilization previously. 10 Subsequently, a randomized trial compared plerixafor with G-CSF, vs G-CSF alone, as an upfront strategy for mobilization of HSC. 11 In this study, the combination of plerixafor with G-CSF successfully mobilized a minimum of 5 million CD34 þ cells/kg in 59% of patients with non-Hodgkin's lymphoma, in comparison with 29% in the G-CSF alone arm, a difference that was statistically significant. 12 With the availability of plerixafor for stem cell mobilization, most patients are now able to yield stem cells successfully; however, the question remains whether plerixafor is needed for every patient for HSC mobilization. This is particularly important owing to the high cost associated with the drug. As approximately 15-30% of patients fail to mobilize adequately with G-CSF alone, one strategy would be to limit the use of plerixafor to patients who have failed initial mobilization. However, remobilization is costly 13 and adds a significant delay in proceeding to transplantation. Another strategy would be to identify potential poor mobilizers upfront, and target the use of plerixafor to this population. 14 In our experience, the day 5 count of circulating CD34 þ cells/mL after 4 days of G-CSF predicted the success of HSC mobilization, as has been described by others. 15, 16 We used this number to identify patients at risk of failure of adequate mobilization. Patients who had less than 5 circulating CD34 þ cells/mL invariably failed to achieve adequate stem cell collection that day and were very likely to be mobilization failures. Patients who had a circulating CD34 þ count between 5 and 10 cells/mL after 4 days of G-CSF were most likely to have successful collections over several days, whereas those with CD34 þ counts greater than 20 cells/mL almost always achieved adequate collection yields. Similar findings have been reported from other centers. 13, 17 Applying this approach, we developed a practical risk-based algorithm shown in Table 1 , with the following goals: (1) to identify likely poor and slow mobilizers upfront, and use plerixafor in these selected patients; (2) to minimize the number of days needed for adequate HSC collection.
Materials and methods
Institutional Review Board approval from the University of Kansas Medical Center was obtained for the purpose of this analysis. A treatment algorithm was developed using the circulating CD34 þ cell count on day 5 of G-CSF mobilization, to serve as a marker for poor mobilization and trigger the use of plerixafor (Table 1) . HSCs were mobilized with the use of G-CSF at 10 mcg/kg per day for 4 days. Peripheral blood circulating CD34 þ cells were enumerated in the morning of day 5, using established ISHAGE methodology with a five-color Beckman Coulter 500 FC flow cytometer (Beckman Coulter, Brea, CA, USA). 18 The plerixafor algorithm as outlined in Table 1 takes into account the number of circulating CD34 þ cells/mL on day 5 of G-CSF mobilization, the desired total number of CD34 þ cells/kg needed for transplant (X2.5 million CD34
þ /kg for single transplant and X5 million CD34 þ /kg for more than one transplant) and the day 1 CD34 þ collection yield. Thus, a day 5 CD34 þ circulating level of o10/mL (for one transplant), or o20/mL (for more than one transplant), or the day 1 CD34 þ collection of less than one-half of the total CD34 þ dose needed, prompted the use of plerixafor that evening.
Plerixafor dose was 240 mcg/kg, with a maximum dose of 24 mg given approximately at 1700 hours on the day before the collection process 15 and was continued with daily G-CSF at 10 mcg/kg until the adequate number of CD34 þ cells was collected. All patients underwent apheresis with 4-6 blood volumes processed. Statistical analysis for significance using the paired t-test was done using Microsoft Excel spreadsheets and statistical software.
Results
Between April 2009 and December 2010, a total of 168 patients underwent PBSC mobilization for the purpose of an autologous HSC transplant at the University of Kansas Medical Center. Of these, five patients had HSC harvest done after mobilization with chemotherapy and G-CSF (due to persistent disease) and were excluded from this analysis. Four patients received Plerixafor upfront due to previous therapy with lenalidomide or a history of slow count recovery with their previous treatments and were also excluded from this data analysis. Of the 159 patients that remained, 79 had multiple myeloma, 76 had lymphoma (non-Hodgkin's lymphoma, Hodgkin's disease) and 3 had germ cell tumors and 1 Ewing's sarcoma. The median patient age was 56 years (range, 19-72), and included 110 males and 49 females. Overall patient characteristics are illustrated in Table 2 .
Of the 159 patients, 55 (34.5%) were given plerixafor based on the algorithm guidelines-39 patients due to peripheral CD34 þ counts of o10/mL on day 1 of collection; Table 3 ). The median number of days to collect adequate HSC in the two groups was 2 in the plerixafor arm and 1 in the G-CSF alone arm. Furthermore, for patients requiring X2.5 Â 10 6 CD34 þ cells/kg (one transplant), the median number of CD34 þ cells collected was 2.84 Â 10 6 /kg for lymphoma and 2.96 Â 10 6 /kg for myeloma in the plerixafor and G-CSF arm, compared with /kg (P ¼ 0.321), respectively, in the G-CSF alone arm. For patients requiring X5.0 Â 10 6 CD34 þ cells/kg (more than one transplant), the median number of CD34 þ cells collected was 6.46 Â 10 6 in the plerixafor with G-CSF arm, in comparison with 6.27 Â 10 6 in the G-CSF alone arm (P ¼ 0.378). Further breakdown of the number of CD34 þ cells collected, the number of days to desired collection, and the details for other diagnoses in patients are listed in Table 3 . We reviewed the days for WBC and platelet engraftment post transplant between the two groups and found them to be similar (Table 2) .
Patients who received plerixafor with G-CSF had a median 1.46-fold increase (P ¼ 0.1) in the number of circulating peripheral CD34 þ cells on the day after the plerixafor administration (range, 0.23-3.76-fold increase), compared with the initial CD34 þ counts after 4 days of G-CSF alone. We also evaluated the number of days required to achieve an adequate HSC collection in patients on this algorithm, compared with historical control data from our institution. The use of this algorithm reduced the median number of days required to obtain an adequate HSC collection to 1.7 days from the historical time of 3 days (P ¼ 0.001). The combination of plerixafor with G-CSF resulted in a remobilization rate of 5%, which compared favorably with our historical rate of approximately 19%.
Discussion
Plerixafor works synergistically with G-CSF and results in adequate stem cell collections in a majority of patients, as was shown in pivotal studies that resulted in the FDA approval of the drug for autologous HSC harvests for myeloma and lymphoma. 11, 12 The drug may not be needed in all patients undergoing HSC collections, and there are very significant cost implications with the administration of the drug. There is also the theoretical risk of mobilization and collection of malignant cells along with the HSC with CXCR4 antagonists. 16, 19 We developed a risk-based plerixafor use algorithm to optimize the use of the drug to suitable patients who most likely need it, viz. those who are potential mobilization failures, thereby avoiding the need to re-mobilize HSC and also not utilize the drug on every patient undergoing an autologous HSC collection. We also developed the algorithm to minimize the number of days it takes for an adequate stem cell collection, and wanted it be practical so it will be easy to use by the clinical staff. We took into account the day 1 circulating CD34 þ cell count as well as the total CD34 þ cell dose collected as a guide to identify potential poor and slow mobilizers. Previous observations showed that the circulating CD34 þ count after 4 days of G-CSF correlates with the total CD34 þ cells collected. 13, 17 Following this algorithm, our center limited the use of plerixafor to about 35% of the patients who were undergoing HSC mobilization. By developing and implementing this risk-stratified algorithm, we have been able to reduce the number of patients who need remobilization from 19 to 5%, and reduce costs associated with remobilization. Out of the 55 patients treated with plerixafor per the algorithm, 47 were able to mobilize an adequate number of CD34 þ cells at the first attempt. In these patients, there is a cost and time saving as compared with those who fail to mobilize on their first attempt and then undergo a second mobilization. Cost saving has also been shown in other studies comparing chemo-mobilization to plerixafor mobilization. 20 We have also shown that with the use of this riskbased approach, our center has been able to improve on the number of days required to achieve an adequate collection of HSC. Thus, the median number of days required to collect adequate HSC has dropped over the last 2 years from 3 to 1.7, making the HSC mobilization part of the autologous transplant procedure more predictable and timely and freeing up more time on the apheresis machine.
This algorithm decreased the need for additional apheresis collection days, minimized delays, reduced re-mobilization, ameliorated the degree of anxiety that is often associated with mobilization failure and has made the HSC collection process at our institution more predictable. Furthermore, targeting the use of plerixafor to selected patients reduces the overall costs associated with autologous transplant procedures for a BMT program by avoiding its use in all patients. Some factors may limit the application of this algorithm across institutions, as this approach relies on the availability of CD34 þ cell enumeration by flow cytometry in a timely manner on the morning of the first day of collection. However, this study does provide the components necessary to develop institutional protocols for validation of similar practical approaches to using plerixafor.
